Loading...
SELLAS Life Sciences Group, Inc.
SLS•NASDAQ
Healthcare
Biotechnology
$4.13
$-0.08(-1.90%)
U.S. Market opens in 15h 5mSELLAS Life Sciences Group, Inc. (SLS) AI-Powered Stock Analysis
See how SELLAS Life Sciences Group, Inc. scores across key metrics like financial growth, valuation, and market position using AI-driven evaluation.
Model Information
The AI Stock Analysis Model is provided for informational purposes only and should not be considered financial advice. We are continously improving this model to increase accuracy and performance.Read our Full DisclaimerSELLAS Life Sciences Group, Inc. (SLS) Stock Overall Grade
SELLAS Life Sciences Group, Inc.’s grade based on a comprehensive AI analysis of financial metrics, growth potential, and market position.
Z
Grade Breakdown by Metric
See how each financial and market factor contributes to SELLAS Life Sciences Group, Inc.'s overall stock rating.
Forecast
C+Score
56/100Financial Growth
AScore
80/100Fundamental Growth
C+Score
56/100Key Ratios
C+Score
55/100Sector Comparison
B+Score
75/100Industry Comparison
C+Score
50/100S&P 500 Benchmark
A+Score
94/100Analyst Consensus
C+Score
50/100SELLAS Life Sciences Group, Inc. (SLS) AI-Powered Stock Analysis
This asset demonstrates Good performance with an overall Forecast Score of 56/100 (C+), reflecting weak confidence in its potential. Financial Growth (80/100, A) and Fundamental Growth (56/100, C+) highlight its stability, while Key Ratios (55/100, C+) and Sector Comparison (75/100, B+) indicate solid positioning. Compared to broader benchmarks like the S&P 500 (94/100, A+), it shows competitive strength. Analyst Consensus (50/100,C+) suggests High divergence in outlook.Component Analysis Explained
Understand the key factors behind each SELLAS Life Sciences Group, Inc. stock grade, including financials, comparisons, and forecasts.